Fat loss
Semaglutide: oral ↔ injectable
Not a stack. One compound, two routes, and a switching protocol written into the approved label. The windows differ depending on which direction you are going, and the reason is pharmacology rather than caution.
At a glance
- What is in it
- Sold as
- Separate vials
- The evidence
- This comes from the Wegovy prescribing information, revised June 2026, not from a vendor page and not from community practice. It is the only route-switch protocol in this library with a label behind it.Combination-specific research is limited. Treat each compound’s evidence as separate unless a study of the combination itself is named here, and review the complete plan with a qualified clinician.
Running this stack, with the schedule, the vials it takes and a log of what you took, happens in the app: Claritide for iPhone.
Why people explore it
Common reasons for exploring it
- Anyone prescribed semaglutide who is changing route
- Anyone who wants to see what a properly specified administration protocol looks like, against the vendor-tier protocols elsewhere in this library
Where clinician input matters
- Anyone doing this without a prescriber. The switching windows are label instructions to a clinician, not a self-managed adjustment.
- Anyone assuming the tablet carries the injection's indications
The science
Read the compound mechanisms
Semaglutide mimics GLP-1, a hormone your gut releases after eating, with 94% homology to the human peptide. Activating GLP-1 receptors in the brain reduces appetite and increases fullness. It slows gastric emptying, so meals feel filling for longer. And it both increases insulin secretion and reduces glucagon secretion in a glucose-dependent way, which is why the same molecule treats type 2 diabetes. A C18 fatty di-acid chain at position 26 binds it to albumin, which is what stretches the half-life to about a week; position 8 is modified to resist the DPP-4 enzyme that clears natural GLP-1 in minutes. It is a single-receptor drug. That is the difference from tirzepatide and retatrutide, and it is why its weight-loss figure is smaller.
Commonly researched ranges
- Semaglutide2.4 (injection) / 25 (tablet) mgPrescription
| Compound | Amount | Frequency | Timing |
|---|---|---|---|
| SemaglutidePrescription | 2.4 (injection) / 25 (tablet) mg | Once weekly injection, or once daily tablet | Tablets: fasted in the morning, no more than 4 oz of water, swallowed whole, then no food, drink or other oral medication for at least 30 minutes. |
- Semaglutide: Injection to tablets: one week after the last 2.4 mg injection, start 25 mg tablets once daily. Tablets to injection: the day after stopping 25 mg tablets, start 2.4 mg subcutaneously weekly, or 1.7 mg if the 25 mg tablet was not tolerated. Tablet titration runs 1.5 mg on days 1–30, 4 mg on days 31–60, 9 mg on days 61–90, and 25 mg maintenance from day 91.
- Duration
- Ongoing. Semaglutide's half-life is about one week and it remains in circulation for 5–7 weeks after the last dose, which is why the two switch windows are not symmetrical.
Mixing each compound
Not established in available literature. Use the figures printed on your own vial.
Week by week
Semaglutide
- Week 1–16
Escalation through four steps. Nausea is most likely here and settles: it affected 44% of people against 16% on placebo, and it is the reason the schedule climbs slowly rather than starting at the target.
- Week 17
Maintenance dose reached, 2.4 mg or 1.7 mg weekly depending on what it was prescribed for.
- Week 60–68
Weight loss flattens around here. STEP 1 showed 14.9% mean reduction at 68 weeks on 2.4 mg, against 2.4% on placebo.
What it costs
- Semaglutide: $349–1349 per month
Cautions
- The indications are not the same across routes. The MASH indication (noncirrhotic, moderate-to-advanced fibrosis) and the paediatric 12-and-over indication apply to the WEGOVY injection only. The tablets carry neither. A reader on the 25 mg tablet could otherwise believe they are being treated for liver disease.
- The tablet administration constraints are the protocol, not a suggestion: fasted, in the morning, no more than 4 oz of water, swallowed whole, 30-minute lockout before anything else by mouth including other medications.
- The injection route escalates further than most people realise: 7.2 mg/0.75 mL weekly is available after at least four weeks of tolerating 2.4 mg, and there is a 9.6 mg/3 mL multi-dose pen.
- Label changes worth knowing: suicidal behaviour and ideation was REMOVED from the warnings section in February 2026. The same removal appears on the Zepbound and generic liraglutide labels. Acute kidney injury from volume depletion was added in August 2025. Severe gastrointestinal adverse reactions, including "not recommended in patients with severe gastroparesis", was added in October 2025. A "never share the pen" warning was added in June 2026.
- Pulmonary aspiration during general anaesthesia or deep sedation is on the label. Tell your anaesthetist or endoscopist that you take this and when you last dosed.
- Discontinue at least two months before a planned pregnancy.
- NAION: the strongest verified statement is that the European Medicines Agency recommended adding it to semaglutide labelling as a very rare side effect in June 2025. It does not appear in the US Wegovy warnings block, and we do not say that it does.
Absence from this list does NOT mean safety. It means lack of research.
Every stack here is free to read, and it stays free. Your own schedule, vials and log live in the app: Claritide for iPhone.